UK markets closed
  • NIKKEI 225

    29,018.33
    -272.68 (-0.93%)
     
  • HANG SENG

    28,558.59
    +121.75 (+0.43%)
     
  • CRUDE OIL

    71.14
    -1.01 (-1.40%)
     
  • GOLD FUTURES

    1,778.20
    -83.20 (-4.47%)
     
  • DOW

    33,873.22
    -160.45 (-0.47%)
     
  • BTC-GBP

    27,137.38
    -893.59 (-3.19%)
     
  • CMC Crypto 200

    939.16
    -30.72 (-3.17%)
     
  • ^IXIC

    14,175.59
    +135.91 (+0.97%)
     
  • ^FTAS

    4,071.33
    -17.14 (-0.42%)
     

Zealand Pharma to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Company announcement – No. 36/ 2021

Zealand Pharma to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Copenhagen, DK and Boston, MA, U.S. June 3, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the Goldman Sachs 42nd Annual Global Healthcare Conference:

Goldman Sachs 42nd Annual Global Healthcare Conference

Date: Thursday, June 10, 2021

Presentation: 9:40 a.m. ET / 3:40 p.m. CET

A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor Relations

Claudia Styslinger

Argot Partners

investors@zealandpharma.com

Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting